Opko to Buy Non-RNAi Drug Assets from Schering-Plough

According to Opko, Schering-Plough is making the divestiture, which includes the phase II chemotherapy-related nausea and vomiting prophylactic rolapitant, in order to meet certain requirements for its expected merger with Merck.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories